

Institution	Scanner Models	Number of Scanners
UCSD CTIPM	GE Healthcare Discovery MR750, GE Healthcare Signa Premier	4
UCSD Health	GE Healthcare Discovery MR750, GE Healthcare Signa Premier	4
URMC	SIEMENS Magnetom Skyra	2
MGH	GE Healthcare Signa Premier	1
UCSF	GE Healthcare Signa Premier	2
Cambridge	GE Healthcare Discovery MR750	1
UTHSCSA	SIEMENS Magnetom Skyra, SIEMENS Magnetom Trio	3

Cambridge	DWI	T2-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	4500	3130
TE (ms)	59	98
Voxel Size (mm)	2.29 x 2.29 x 4	0.4 x 0.7 x 3

<i>b</i> -values (s/mm ²) [number of samples]	0[1], 500[6], 1000[6], 2000[12]	N/A
Field Strength (T)	3	3
Scanner Manufacturer/Model	GE Healthcare/Discovery MR750	GE Healthcare/Discovery MR750
MGH	DWI	T2-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	4500	3937
TE (ms)	59	169
Voxel Size	2.5 x 2.5 x 6	0.44 x 0.71 x 3
<i>b</i> -values (s/mm ²) [number of samples]	0[1],500[8],1000[8],2000[16]	N/A
Field Strength (T)	3	3
Scanner Manufacturer/Model	GE Healthcare/Signa Premier	GE Healthcare/Signa Premier
UCSD CTIPM_Discovery1/UCSDH_Discovery1	DWI	T2-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	4500	7000
TE (ms)	69	100
Voxel Size (mm)	2.5 x 2.5 x 6	0.75 x 0.75 x 3
<i>b</i> -values (s/mm ²) [number of samples]	0[1], 500[6], 1000[6], 2000[12]	N/A
Field Strength (T)	3	3
Scanner Manufacturer/Model	GE Healthcare/Discovery MR750	GE Healthcare/Discovery MR750
UCSD CTIPM_Discovery2	DWI	T2-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	4500	6230
TE (ms)	76	98
Voxel Size (mm)	2.5 x 2.08 x 3	0.75 x 0.75 x 3
<i>b</i> -values (s/mm ²) [number of samples]	0 [1], 50[6], 800[6], 1500[12], 3000 [18]	N/A
Field Strength (T)	3	3
Scanner Manufacturer/Model	GE Healthcare/Discovery MR750	GE Healthcare/Discovery MR750
UCSDH_Premier	DWI	T2-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	4500	3423
TE (ms)	59	170
Voxel Size (mm)	1.9656 x 2 x 4	0.45 x 0.7 x 3

<i>b</i> -values (s/mm ²) [number of samples]	0[1], 500[6], 1000[6], 2000[12]	N/A
Field Strength (T)	3	3
Scanner Manufacturer/Model	GE Healthcare/Signa Premier	GE Healthcare/Signa Premier
UCSF/UCSD CTIPM_Premier	DWI	T2-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	4500	2964
TE (ms)	75	150
Voxel Size (mm)	2.5 x 2.5 x 3	0.43 x 0.43 x 3
<i>b</i> -values (s/mm ²) [number of samples]	0[5], 100[6], 800[12], 1400[12], 2500[18]	N/A
Field Strength (T)	3	3
Scanner Manufacturer/Model	GE Healthcare/Signa Premier	GE Healthcare/Signa Premier
URMC	DWI	T2-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	3800	4800
TE (ms)	85	104
Voxel Size (mm)	1 x 1 x 4	0.47 x 0.49 x 3
<i>b</i> -values (s/mm ²) [number of samples]	0[1], 500[6], 1000[6], 2000[6]	N/A
Field Strength (T)	3	3
Scanner Manufacturer/Model	SIEMENS Healthcare/Magnetom Skyra	SIEMENS Healthcare/Magnetom Skyra
UTSA_Skyra	DWI	T2-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	6300	4710
TE (ms)	105	100
Voxel Size (mm)	1 x 1 x 4	0.75 x 0.56 x 3
<i>b</i> -values (s/mm ²) [number of samples]	0[1], 500[6], 1000[18], 2000[42]	N/A
Field Strength (T)	3	3
Scanner Manufacturer/Model	SIEMENS Healthcare/Magnetom Skyra	SIEMENS Healthcare/Magnetom Skyra
UTSA_Trio	DWI	T2-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	98	1800
TE (ms)	5500	203
Voxel Size (mm)	2.3438 x 2.3438 x 3	0.68 x 0.68 x 1.5

<i>b</i> -values (s/mm ²) [number of samples]	0[1], 500[30], 1000[30], 2000[30]	N/A
Field Strength (T)	3	3
Scanner Manufacturer/Model	SIEMENS Healthcare/Magnetom Trio	SIEMENS Healthcare/Magnetom Trio

Supplementary Table 1. Detailed Breakdown of MRI parameters for all acquisition groups. *N/A* signifies the parameter was not relevant for the acquisition. Parameters may differ between patient MRI scans.

Abbreviations: TR (Repetition Time), TE (Echo Time), FSE (Fast Spin Echo), EPI (Echo Planar Imaging),

Cambridge (University of Cambridge), MGH (Harvard University’s Massachusetts General Hospital),

UCSD[H] (University of California San Diego [Health]), CTIPM (Center for Translational Imaging and

Precision Medicine), UCSF (University of California San Francisco), UPMC (University of Pittsburgh Medical

Center), UTHSCSA (University of Texas Health Sciences Center San Antonio).

Model	All Patients (RSIrs99)
Formula	
	RSIrs99 ~ 5-ARI use + Age + Prostate volume + Race/Ethnicity group + Grade group + Acquisition group
Age [reference = mean, 69 years old]	
	1.07* [0.04, 2.11]
Prostate Volume [reference = mean, 60 mL]	
	-0.80*** [-1.08, -0.52]
5-ARI Use [reference = Not used]	
On Use within 6 months of MRI	29.69 [-15.78, 75.16]
Race/Ethnicity Group [reference = White Non-Hispanic]	
Asian	14.25 [-19.70, 48.20]
Black	6.51 [-22.25, 35.26]
White Hispanic	-13.34 [-46.76, 20.07]
Grade Group [reference = Benign]	
1	8.43 [-16.11, 33.01]
2	31.77** [9.18, 54.36]
3	56.51*** [30.12, 82.91]
4	112.78*** [72.451, 153.10]
5	182.8*** [149.12, 216.48]
Acquisition Group [reference = UCSD CTIPM_Discovery1]	
MGH	43.51 [-24.12, 111.14]


UCSD CTIPM _{Discovery2}	-68.54*** [-98.85, -38.23]
UCSDH _{Premier}	29.12 [-1.99, 60.22]
UCSF/UCSD CTIPM _{Premier}	-41.67** [-72.9, -10.43]
URMC	33.33** [12.39, 54.28]
UTSA _{Skyra}	-39.66 [-83.89, 4.57]
UTSA _{Trio}	-45.05** [-77.01, -13.07]

Supplementary Table 2. All predictors and their estimated effects on the 99th percentile RSIRs identified using multiple linear regression modeling [Method 2]. These predictors included 5-ARI (current 5-ARI usage or usage <6 months before MRI), age, prostate volume, race/ethnicity, grade group, and acquisition group. Coefficient estimates [95% confidence interval] are reported for each significant effect, which provide insight into the impact of these variables on RSIRs. *N/A* signifies there were no representative patients of that category included in the analysis. Significant predictors: * ($p < 0.05$), ** ($p < 0.01$), *** ($p < 0.001$)

Model used for Adjustments	Median AUC (Pre-Adjustment)	Median AUC (Post-Adjustment)	Median AUC Difference
Voxel-wise model in patients without csPCa [Method 1]	0.76 [0.74, 0.78]	0.77 [0.75, 0.79]	0.007 [0.006, 0.009]
Patient-level model of RSIRs _{max} using all patients [Method 2]	0.74 [0.72, 0.76]	0.73 [0.70, 0.75]	-0.01 [-0.02, -0.005]

Supplementary Table 3. Results from two 10,000-bootstrap analyses using subgroups of patients with significant acquisition and patient effects on RSIRs estimated with two methods, respectively. Each patient was matched with one in the reference population, stratified by grade group. A bootstrap sample size of 1000 was used. Adjustments were made using a linear transformation based on significant acquisition and patient effects identified by two different estimation methods, allowing comparison of AUC values pre- and post-adjustment.

This reflects the impact of both acquisition and patient effects.



Supplementary Figure 1. Sample size estimation analysis for an acquisition group from University of Rochester Medical Center (URMC). In this analysis, 10,000 bootstrap samples ranging from $n = 1:251$ were taken. The line on the graph represents the median effect estimate for each set of 10,000 bootstrap samples (RSIrs), while the blue shading indicates the 95% Confidence Interval for each set of 10,000 bootstrap samples. The red dotted lines represent the mean 95% Confidence Interval of all sets of bootstrap samples. The red circle denotes the location of the minimum estimated sample size required to accurately reproduce the acquisition effects at this institution, defined as where the minimum bootstrap median coefficient estimate that is within 1% of the value observed for the total population ($n=251$). Accurate estimation of acquisition effects requires only 29 patients.